SLAS Discovery

metrics 2024

Exploring New Horizons in Molecular Medicine

Introduction

SLAS Discovery is a leading academic journal published by Elsevier Science Inc. that serves as a pivotal resource in the fields of Analytical Chemistry, Biochemistry, Biotechnology, and Molecular Medicine. Since its inception in 2017, the journal has become increasingly influential, attaining a Q1 ranking in Analytical Chemistry and notable Q2 rankings in the associated fields as of 2023. With an impressive Scopus rank that places it within the top percentile of its categories, SLAS Discovery highlights groundbreaking research and methodologies impacting drug discovery and development. The journal advocates for open access, ensuring that its curated content is widely available to the scientific community, fostering collaboration and innovation. Researchers, professionals, and students alike will find value in the journal's comprehensive reviews and original research articles that contribute to the advancement of scientific knowledge and applications in life sciences.

Metrics 2024

SCIMAGO Journal Rank0.87
Journal Impact Factor2.70
Journal Impact Factor (5 years)2.80
H-Index33
Journal IF Without Self2.70
Eigen Factor0.00
Normal Eigen Factor0.59
Influence0.74
Immediacy Index1.30
Cited Half Life3.90
Citing Half Life7.10
JCI0.70
Total Documents649
WOS Total Citations1603
SCIMAGO Total Citations4197
SCIMAGO SELF Citations255
Scopus Journal Rank0.87
Cites / Document (2 Years)2.86
Cites / Document (3 Years)2.87
Cites / Document (4 Years)2.97

Metrics History

Rank 2024

Scopus

Analytical Chemistry in Chemistry
Rank #39/156
Percentile 75.00
Quartile Q2
Biotechnology in Biochemistry, Genetics and Molecular Biology
Rank #95/311
Percentile 69.45
Quartile Q2
Biochemistry in Biochemistry, Genetics and Molecular Biology
Rank #140/438
Percentile 68.04
Quartile Q2
Molecular Medicine in Biochemistry, Genetics and Molecular Biology
Rank #64/178
Percentile 64.04
Quartile Q2

IF (Web Of Science)

BIOCHEMICAL RESEARCH METHODS
Rank 38/85
Percentile 55.90
Quartile Q2
BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Rank 90/174
Percentile 48.60
Quartile Q3
CHEMISTRY, ANALYTICAL
Rank 49/106
Percentile 54.20
Quartile Q2

JCI (Web Of Science)

BIOCHEMICAL RESEARCH METHODS
Rank 39/85
Percentile 54.12
Quartile Q2
BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Rank 78/174
Percentile 55.17
Quartile Q2
CHEMISTRY, ANALYTICAL
Rank 43/106
Percentile 59.43
Quartile Q2

Quartile History

Similar Journals

Current Computer-Aided Drug Design

Innovating Therapeutics: The Future of Drug Design Starts Here
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1573-4099Frequency: 4 issues/year

Current Computer-Aided Drug Design, published by BENTHAM SCIENCE PUBL LTD, is a pivotal journal dedicated to the integration of computer-aided methodologies within the drug design process. With its ISSN 1573-4099 and E-ISSN 1875-6697, this journal serves as a vital resource for researchers, professionals, and students interested in advancing the fields of pharmacology and molecular medicine. Operating under a framework that spans from 2006 to 2024, it aims to foster innovative approaches and discussions surrounding drug design strategies, computational techniques, and the therapeutic potential of novel compounds. Although it currently holds a Q4 rating in Drug Discovery and Molecular Medicine as well as a Q3 in Medicine (miscellaneous) within the 2023 category quartiles, the journal continues to enhance its visibility and relevance in the academic community. Its Scopus rankings reflect its commitment to quality research, positioning it in the context of drug discovery and molecular studies. As the field of drug design evolves, Current Computer-Aided Drug Design remains an essential platform for disseminating cutting-edge findings and facilitating collaboration among specialists aiming for significant advancements in drug development.

MOLECULAR & CELLULAR PROTEOMICS

Elevating the discourse in molecular and cellular proteomics.
Publisher: ELSEVIERISSN: Frequency: 1 issue/year

MOLECULAR & CELLULAR PROTEOMICS, published by Elsevier, stands as a premier journal in the fields of Biochemistry, Analytical Chemistry, and Molecular Biology, with a distinguished Q1 ranking reflecting its high impact and contribution to the scientific community. Established in 2002, this journal has consistently provided a platform for the latest research in protein science, merging molecular biology with advanced analytical techniques. With impressive Scopus rankings—41st in Biochemistry and 16th in Analytical Chemistry—it caters to an audience of researchers, professionals, and students eager to explore cutting-edge developments in proteomics. Although currently not designated as open access, the journal aims to foster knowledge dissemination through accessible research content. As it continues to evolve until 2024, MOLECULAR & CELLULAR PROTEOMICS is essential for anyone passionately engaged in the ever-expanding field of proteomics.

MOLECULAR AND CELLULAR PROBES

Connecting Researchers to Cutting-edge Cellular Science
Publisher: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTDISSN: 0890-8508Frequency: 6 issues/year

MOLECULAR AND CELLULAR PROBES, published by Academic Press Ltd - Elsevier Science Ltd, stands as a prominent journal at the intersection of cell and molecular biology. With an ISSN of 0890-8508 and an E-ISSN of 1096-1194, this journal has consistently contributed to the scientific discourse since its inception in 1987, converging its scholarly content through to 2024. As a member of Q3 in both Cell Biology and Molecular Biology categories, it provides a platform for innovative research and critical insights into cellular mechanisms, signaling pathways, and molecular interactions. Its Scopus rankings position it within the top half of its categories, fostering a vibrant academic community that supports the exploration and advancement of biochemistry, genetics, and molecular biology. Although it does not currently offer Open Access, the high-quality peer-reviewed articles published in MOLECULAR AND CELLULAR PROBES are invaluable resources for researchers, professionals, and students who seek to stay at the forefront of breakthroughs in these essential fields.

Computational and Structural Biotechnology Journal

Innovating at the Nexus of Computer Science and Molecular Biology
Publisher: ELSEVIERISSN: 2001-0370Frequency:

Computational and Structural Biotechnology Journal is a premier open-access journal published by Elsevier, focusing on the intersection of computer science and molecular biology. Since its inception in 2012, the journal has established itself as a leading platform for innovative research, featuring groundbreaking studies in biochemistry, biophysics, biotechnology, and genetics. With a remarkable Q1 ranking in multiple categories, including Biochemistry and Genetics, it stands out for its high impact, evidenced by its strong Scopus ranking percentile scores. As a vital resource for researchers, professionals, and students, the journal aims to foster the dissemination of essential findings that leverage computational techniques to explore complex biological systems. In a rapidly evolving scientific landscape, Computational and Structural Biotechnology Journal serves as an indispensable resource for those looking to contribute and stay abreast of major advancements in the field.

JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

Empowering Drug Discovery with Cutting-Edge Design Techniques
Publisher: SPRINGERISSN: 0920-654XFrequency: 12 issues/year

JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, published by Springer, serves as a premier platform for researchers in the fields of computer science applications, drug discovery, and physical and theoretical chemistry. Since its inception in 1987, the journal has played a pivotal role in advancing the methodologies and technologies used in molecular design and screening. With an impressive impact factor and a ranking within the top quartile across related disciplines, this journal offers invaluable insights and innovative approaches that are essential for scholars and practitioners in these dynamic fields. The journal's rigorous peer-review process ensures high-quality publications that contribute significantly to both theoretical and practical advancements. Though it operates under a subscription model, the journal remains dedicated to fostering knowledge dissemination and collaboration among researchers.

Expert Opinion on Drug Discovery

Exploring the Frontiers of Pharmacological Science
Publisher: TAYLOR & FRANCIS LTDISSN: 1746-0441Frequency: 6 issues/year

Expert Opinion on Drug Discovery, published by Taylor & Francis Ltd, is a premier journal dedicated to the rapidly evolving field of drug development and innovation. With a strong emphasis on the integration of multidisciplinary approaches in pharmacology and toxicology, the journal has established itself as an invaluable resource for researchers, professionals, and students alike. Its impressive impact factor and classification as a Q1 journal in drug discovery, alongside its high Scopus ranking (Rank #20/157, Percentile 87th), underscore its significance within the academic community. Spanning from 2006 to 2024, Expert Opinion on Drug Discovery features a wide range of expert reviews and opinion articles that provide insights into the latest trends and breakthroughs in drug discovery, fostering collaboration and knowledge exchange. While the journal is not open access, it plays a critical role in shaping the future of drug development, making it an essential platform for those seeking to deepen their understanding of this dynamic field.

Journal of Cheminformatics

Unveiling the potential of cheminformatics for all.
Publisher: BMCISSN: 1758-2946Frequency: 1 issue/year

Journal of Cheminformatics, published by BMC, is a premier open-access journal that has been a cornerstone of cheminformatics research since its inception in 2009. With an ISSN of 1758-2946, this journal operates from the heart of the United Kingdom, providing a dynamic platform for disseminating high-quality, peer-reviewed articles that explore the integration of computer science with chemistry. The journal proudly stands in the prestigious Q1 category across multiple disciplines, including Computer Graphics, Computer-Aided Design, and Library and Information Sciences, showcasing its exceptional impact in the fields of cheminformatics and computational chemistry. Additionally, it ranks impressively in various Scopus categories, with notable placements such as #7 in Library and Information Sciences and #15 in Physical and Theoretical Chemistry, demonstrating its significance to the academic community. As a leader in open-access publishing, the Journal of Cheminformatics ensures that cutting-edge research and innovations are freely accessible to researchers, professionals, and students alike, fostering collaboration and advancement in this rapidly evolving field.

NATURAL PRODUCT RESEARCH

Exploring the Essence of Nature's Compounds
Publisher: TAYLOR & FRANCIS LTDISSN: 1478-6419Frequency: 24 issues/year

NATURAL PRODUCT RESEARCH is a distinguished journal published by Taylor & Francis Ltd, dedicated to advancing the field of natural product science through the dissemination of high-quality research. Established in 2003, this journal serves as a pivotal platform for scholars in Analytical Chemistry, Biochemistry, Organic Chemistry, and Plant Science, boasting an impressive categorization including Q2 in Plant Science and Q3 in the other disciplines for 2023. With a current Scopus ranking that highlights its significance within various scientific communities, NATURAL PRODUCT RESEARCH reflects the complexities and innovations associated with natural compounds and their applications. Researchers, professionals, and students will find valuable insights and breakthroughs that contribute to the understanding of bioactive compounds and their roles in health and environmental sustainability. Access options are available, ensuring that the latest findings are accessible to a global audience. As this journal continues to publish until 2024, it remains an essential resource for those at the forefront of natural product research.

Letters in Drug Design & Discovery

Exploring New Horizons in Molecular Medicine
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1570-1808Frequency: 12 issues/year

Letters in Drug Design & Discovery is an esteemed journal dedicated to advancing the fields of Drug Discovery and Molecular Medicine. Published by Bentham Science Publishers, this journal offers a platform for the dissemination of innovative research and advanced methodologies, enhancing collaboration among researchers and professionals in pharmaceutical sciences. Despite its current Q4 ranking in Drug Discovery and Molecular Medicine and Q3 in Pharmaceutical Science for 2023, the journal is committed to improving its presence in the academic community by providing quality, peer-reviewed publications that cover various aspects of drug design and discovery, including novel therapeutic approaches and methodologies. With a focus on both foundational and cutting-edge research from around the globe, Letters in Drug Design & Discovery is pivotal for those seeking to stay abreast of developments in drug development and molecular research. Researchers are encouraged to submit their work, engage with the burgeoning field, and contribute to the ongoing dialogue driven by this journal, which spans the years from 2005 to 2024. While the journal does not currently offer open access, its contributions remain accessible to a wide range of academic and professional audiences.

MEDICINAL RESEARCH REVIEWS

Elevating Biomedical Knowledge through Rigorous Review
Publisher: WILEYISSN: 0198-6325Frequency: 6 issues/year

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.